Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting - Seite 2

• Abstract Title: Detection of MRD assessment with the Personalis NeXT Personal assay using MATRIX plasma-in-plasma contrived samples
  • Session Date & Time: Tuesday, Apr 9, 2024 1:30 PM - 5:00 PM
  • Location: Poster Section 31, Number 20
  • Abstract Number: 6094

Biopharma partner blinded study showed NeXT Personal’s ability to detect ultra-low levels of ctDNA.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Forward-Looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the NeXT Personal assay, the potential for NeXT Personal to detect recurrent cancer earlier or monitor response in cancer patients receiving immunotherapy, the ability of NeXT Personal to detect ultra-low levels of ctDNA with high specificity or to predict patient therapy response or outcomes, or other future events. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240328348049/en/

The Personalis Stock at the time of publication of the news with a raise of +1,43 % to 1,344EUR on Tradegate stock exchange (27. März 2024, 22:26 Uhr).